Bespoke Research on China and neighbouring regions, Bixmoor

Bixmoor

Bespoke Research on China and neighbouring regions

Bixmoor specialises in providing bespoke research to business, governments and the financial community on China and neighbouring regions. We seek to build long-term relationships with our clients, based on our expertise, our reliability and our determination to find the right solution.

Thematic (Sector/Industry)

Senior Chinese officials regularly make all the appropriate noises about the evils of illicit drug use in China, but they seem unable to do anything about the massive drug manufacturing operations that take place almost openly in Guangdong province.

Senior Chinese officials regularly make all the appropriate noises about the evils of illicit drug use in China, but they seem unable to do anything about the massive drug manufacturing operations that take place almost openly in Guangdong province.

Breastfeeding rates in China are important, both in terms of stocks and for the health of the country. But how can we trust official statistics from a state agency that appear to contradict each other?

Breastfeeding rates in China are important, both in terms of stocks and for the health of the country. But how can we trust official statistics from a state agency that appear to contradict each other?

Chinese people are actively choosing not to have further children and this will lead inexorably to a population collapse during the balance of this century – a situation not helped by the fact that the state is still damaging its own overdue initiatives with retrogressive “family planning” strategies.

Chinese people are actively choosing not to have further children and this will lead inexorably to a population collapse during the balance of this century – a situation not helped by the fact that the state is still damaging its own overdue initiatives with retrogressive “family planning” strategies. 

Special Situations, Content Strategist, Smartkarma

Crispin Francis

Special Situations, Content Strategist

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Event-Driven

China Nepstar Chain Drugstore / Event-Driven

This is a quick update on <a href="https://www.smartkarma.com/profiles/13" target="_blank" data-smartkarma-citation="accounts:13">Kemp Dolliver's</a> previous insight "<a href="https://www.smartkarma.com/insights/d4903121-73ad-4c04-9709-f47538533949" target="_blank" data-smartkarma-citation="insights:1023">Who's Optimistic About Pharmacy's Future in China? China Nepstar's Controlling Shareholder</a>."<h2>Latest News</h2><blockquote>
SHENZHEN, China, March 16, 2016 /PRNewswire/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD) ("Nepstar" or the "Company"), a leading retail drugstore chain in China based on the number of directly operated stores, announced today that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with China…
</blockquote>

This is a quick update on Kemp Dolliver's previous insight "Who's Optimistic About Pharmacy's Future in China? China Nepstar's Controlling Shareholder."Latest News
SHENZHEN, China, March 16, 2016 /PRNewswire/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD) ("Nepstar" or the "Company"), a leading retail drugstore chain in China based on the number of directly operated stores, announced today that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with China…


Leading Independent Investment Research, Morningstar, Inc.

Morningstar

Leading Independent Investment Research

Morningstar, Inc.

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. We offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors. 

Morningstar provides data on more than 500,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 16 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries, with more than $180 billion in assets under advisement or management as of June 30, 2015. We have operations in 27 countries.

Download the Morningstar Fact Sheet : http://corporate.morningstar.com/US/documents/MarketingFactSheets/AboutMorningstarFactsheet.pdf

What will China look like in 2025? This is a follow up to our <a href="https://www.smartkarma.com/insights/outlook-for-china-10-predictions-for-the-next-10-years" target="_blank" data-smartkarma-citation="insights:2955">Outlook for China:10 Predictions for the Next 10 Years</a> presentation, where we present 10 key data visualisations to back up 10 bold predictions we expect to play out in China over the next 10 years.In this note we provide more background to the thinking behind our predictions.Analyst: Daniel Rohr, CFAChina's faltering economy has sent shivers through the global markets in 2016, and for good reason.As the world's second-largest economy…

What will China look like in 2025? This is a follow up to our Outlook for China:10 Predictions for the Next 10 Years presentation, where we present 10 key data visualisations to back up 10 bold predictions we expect to play out in China over the next 10 years.In this note we provide more background to the thinking behind our predictions.Analyst: Daniel Rohr, CFAChina's faltering economy has sent shivers through the global markets in 2016, and for good reason.As the world's second-largest economy…

China

Shanghai Pharmaceuticals Holding Co., Ltd. manufactures, retails, and wholesales a variety of pharmaceuticals including biopharmaceuticals, chemical and Chinese traditional medicines, and healthcare products. The Company also invests in new medicine development and provides related services.

Shanghai Pharmaceuticals Holding (2607 HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shanghai Pharmaceuticals Holding (2607 HK)

China's Disconnect on Illegal Drugs

Senior Chinese officials regularly make all the appropriate noises about the evils of illicit drug use in China, but they seem unable to do...

Bixmoor

Contradictory Stats on Breastfeeding

Breastfeeding rates in China are important, both in terms of stocks and for the health of the country. But how can we trust official statistics...

Bixmoor

Chinese Choose Not to Have More Children

Chinese people are actively choosing not to have further children and this will lead inexorably to a population collapse during the balance of this...

Bixmoor

Just What the Doctor Ordered

This is a quick update on Kemp Dolliver's previous insight "Who's Optimistic About Pharmacy's Future in China? China Nepstar's Controlling...

Crispin Francis

What Will China Look Like in 2025?

What will China look like in 2025? This is a follow up to our Outlook for China:10 Predictions for the Next 10 Years presentation, where we present...

Morningstar, Inc.

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)